Log ind
Peter Mørch Eriksen.jpg
Foto: BioPorto PR

Increased US activity led to management change in Bioporto

Top picks in English:

Increased activity on the US market is the reason for a change of guards at the helm of the Danish diagnostics group Bioporto’s operations.


BY ANTON GRÆSDAL MAAJEN
Offentliggjort 10.08.16 kl. 11:43

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

“You have to remember that investment is a long-term business”

Kasim_Kutay.jpg Top picks in English:

Although its asset value and net result both dipped significantly in 2016, the new CEO of Novo A/S, Kasim Kutay, is very optimistic on behalf of the company. The long-term trend looks good, he says, and the company is ready to increase investments and bridge the gap between two of its units.

Novo Nordisk jumps on the discount wagon

Top picks in English:

Novo Nordisk’s US unit has struck a deal with CVS Health for a new savings program that will give some patients up to 80 percent reduction on some of the group’s insulin products. It thus looks like times are changing in the Denmark-based insulin giant.

Biotech and CRO outfit Gubra continues explosive growth

Top picks in English:

Thanks to a successful gamble on one particular niche, Denmark’s Gubra has managed to quadruple its employee base in just a few years. The two-pronged business is set to expand significantly in the future.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Saniona gets go ahead for phase IIa trial in obesity disorder

Top picks in English:

Danish biotech Saniona is ready to initiate phase II studies of its lead candidate in a rare disease that leads to obesity and type 2 diabetes. The company aims to add additional endpoints to the study.

Cytovac continues partner search

Top picks in English:

The Danish biotech company Cytovac headed to the BIO-Europe conference in Barcelona hoping to attract potential partners to help it advance its lead asset.

Forsiden lige nu

Amerikansk storinvestor: Genmab er et attraktivt opkøb for de store medicinalselskaber

genmab-office-interior.jpg Medicinal & Biotek:

Interview: Biotekselskabet Genmab kan sagtens ende på andre hænder. Det er i hvert fald meldingen fra Allianz Global Investors, som har en enorm formue under forvaltning.

ALK-partner vil udvide markedet for det største produkthåb

Medicinal & Biotek:

Den danske allergikoncern ALK's japanske partner Torii har indsendt en registreringsansøgning til de japanske sundhedsmyndigheder i bestræbelserne på at udvide markedet for tabletvaccinen Miticure.

Etac-chef efter "fantastisk" år: Det offentlige er blevet mere kvalitetsbevidst

Medico & Rehab:

Den danske Etac-afdeling har afsluttet 2016 med en særdeles pæn vækst og føler, at indkøbsfolkene i regioner og kommuner er blevet mere lydhøre overfor andre argumenter end pris. Til gengæld er Etacs chef nervøs for resten af branchen.

Dansk Aktionærforening: "Novo-bestyrelsen har fejlet"

Medicinal & Biotek:

Hos Dansk Aktionærforening mener man ikke, at bestyrelsen i Novo Nordisk har været sin opgave voksen, og man presser på for at få formand Göran Ando til at takke af.

Novo-fond på vej med milliarder til diabetescentre

Sygdom & Sundhed:

På ét år har Novo Nordisk Fonden firdoblet sine bevillinger til forskningsprojekter og andre formål, der kan forbedre menneskers helbred og velfærd. Og i år vil man på ny sætte rekord i uddelinger.

Fruergaard: Vi skal være bedre til at tilpasse os

Medicinal & Biotek:

Novos Nordisks nye topchef mener selv, at han er kommet godt fra start. Udfordringen er fortsat USA, og der er masser af hårdt arbejde forude i et fortsat svært 2017.

ANNONCE
ANNONCE


ANNONCE